LGVN · XBRL financial data
Longeveron financial statements, every fiscal year
The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (LGVN's year ends in late December)
| In millions of dollars | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|
| Revenue | 1 | 1 | 1 | — | — |
| Revenue from contracts with customers | — | — | 1 | 2 | 1 |
| Cost of revenue | 1 | 1 | 0 | 1 | 0 |
| Gross profit | 1 | 0 | 0 | 2 | 1 |
| Research and development | 7 | 9 | 9 | 8 | 12 |
| General and administrative | 11 | 8 | 11 | 10 | 12 |
| Total operating expenses | 18 | 19 | 21 | 18 | 24 |
| Operating income (loss) | (17) | (18) | (21) | (17) | (23) |
| Interest expense | 0 | 1 | — | — | — |
| Other income (expense) | 0 | (1) | (0) | 1 | 1 |
| Income tax expense (benefit) | — | 0 | 0 | 0 | 0 |
| Net income (loss) | (17) | (19) | (21) | (16) | (23) |
| Earnings per share, basic USD per share | (0.90) | (0.90) | (1.02) | (2.62) | (1.29) |
| Earnings per share, diluted USD per share | (0.90) | (0.90) | (1.02) | (2.62) | (1.29) |
| Weighted average shares, basic millions of shares | 19 | 21 | 22 | 9,411 | 17,577 |
| Weighted average shares, diluted millions of shares | 19 | 21 | 22 | 9,411 | 17,577 |
- † Share count changed about 433x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (LGVN's year ends in late December)
| In millions of dollars | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 26 | 11 | 5 | 19 | 5 |
| Short-term investments | 9 | — | — | — | — |
| Marketable securities | — | 9 | 0 | 0 | — |
| Accounts receivable | 0 | 0 | 0 | 0 | 0 |
| Prepaid and other current assets | 0 | 0 | 0 | 0 | 1 |
| Total current assets | 35 | 20 | 6 | 20 | 5 |
| Property and equipment, net | 3 | 3 | 3 | 2 | 2 |
| Right-of-use asset | 2 | 2 | 1 | 1 | 1 |
| Total assets | 43 | 27 | 12 | 26 | 10 |
| Accounts payable | 1 | 2 | 1 | 0 | 0 |
| Accrued liabilities | 1 | 1 | 2 | 2 | 3 |
| Total current liabilities | 3 | 5 | 4 | 3 | 4 |
| Lease liability, non-current | — | 2 | 1 | 1 | 0 |
| Total liabilities | 5 | 7 | 5 | 4 | 5 |
| Accumulated deficit | (44) | (63) | (85) | (110) | (132) |
| Total stockholders' equity | 37 | 21 | 7 | 22 | 6 |
| Total liabilities and equity | 43 | 27 | 12 | 26 | 10 |
- † Share count changed about 433x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (LGVN's year ends in late December)
| In millions of dollars | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | †Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|
| Net income (loss) | (17) | (19) | (21) | (16) | (23) |
| Stock-based compensation | 1 | 0 | 2 | 2 | 2 |
| Depreciation and amortization | 0 | 0 | 1 | 1 | 1 |
| Net cash from operating activities | (10) | (14) | (19) | (14) | (19) |
| Purchases of property and equipment | 0 | 1 | 0 | 1 | 0 |
| Net cash from investing activities | (11) | (1) | 8 | (1) | (1) |
| Proceeds from issuing common stock | 27 | 0 | 5 | 13 | 5 |
| Net cash from financing activities | 45 | (1) | 5 | 29 | 5 |
- † Share count changed about 433x in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Longeveron | 10 | 0.3 | (5.7)* | not reported | 1.8 quarters | 10-QJun 30, 2026 |
| Lipocine | 5 | 0.2 | (3)* | 8.2M | 7.7 quarters | 10-QJun 30, 2026 |
| Marker Therapeutics | 11 | not reported | (3.7)* | 16.7M | 3.0 quarters | 10-QJun 30, 2026 |
| CalciMedica | 19 | not reported | (4.6)* | 34.1M | 4.0 quarters | 10-QJun 30, 2026 |
| Ernexa Therapeutics | 5 | not reported | (4.2)* | 1.6M | 1.2 quarters | 10-QJun 30, 2026 |
| Charlie's Holdings | 0.5 | not reported | (0.4)* | 280.6M | 1.4 quarters | 10-QJun 30, 2026 |
| Pluri | 3.5 | 0.3* | (4.4)* | 12.3M | 0.8 quarters | 10-KJun 30, 2026 |
| ProPhase Labs | 0 | 1 | (0.1)* | 15.6M | 0.3 quarters | 10-QJun 30, 2026 |
| Akari Therapeutics | 7.7 | not reported | (3.1)* | 155.8B | 2.5 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.